{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:10:25Z","timestamp":1767982225887,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T00:00:00Z","timestamp":1581724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00345-020-03108-z","type":"journal-article","created":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T10:02:28Z","timestamp":1581760948000},"page":"3161-3167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette\u2013Guerin"],"prefix":"10.1007","volume":"38","author":[{"given":"Beppe","family":"Cal\u00f2","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chirico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Carvalho-Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Mota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Est\u00eav\u00e3o","family":"Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Autorino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,15]]},"reference":[{"issue":"5","key":"3108_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM et al (2019) European Association of Urology Guidelines on non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma in situ)\u20142019 update. Eur Urol 76(5):639\u2013657","journal-title":"Eur Urol"},{"key":"3108_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi M, Collette L, Kurth K et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: 207 a combined analysis of seven EORTC 208 studies; EORTC Genito-Urinary Tract Cancer Collaborative Group. Eur Urol 41:523","journal-title":"Eur Urol"},{"key":"3108_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bju.13354","volume":"118","author":"P Gontero","year":"2016","unstructured":"Gontero P, Sylvester R, Pisano F et al (2016) The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/Grade 3 bladder cancer treated with bacille Calmette\u2013Guerin. BJU Int 118:44","journal-title":"BJU Int"},{"key":"3108_CR4","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3389\/fonc.2019.00465","volume":"9","author":"B Cal\u00f2","year":"2019","unstructured":"Cal\u00f2 B, Chirico M, Fortunato F et al (2019) Is repeat transurethral resection always needed in high-grade T1 bladder cancer? Front Oncol 9:465","journal-title":"Front Oncol"},{"key":"3108_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bju.13102","volume":"116","author":"S Baltaci","year":"2015","unstructured":"Baltaci S, Bozlu M, Yildirim A et al (2015) Significance of the interval between first and second transurethral resection on recurrence and progression rates in patients with high-risk non-muscle-invasive bladder cancer treated with maintenance intravesical Bacillus Calmette\u2013Guerin. BJU Int 116:721","journal-title":"BJU Int"},{"key":"3108_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000491642","volume":"102","author":"W Krajewski","year":"2019","unstructured":"Krajewski W, Zdrojowy R, Dembowski J et al (2019) The optimal timing of restaging resection before introduction of bacillus Calmette\u2013Guerin immunotherapy in patients with high-risk non-muscle-invasive bladder cancer. Urol Int 102:60","journal-title":"Urol Int"},{"key":"3108_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA et al (2016) The 2016 WHO classification of tumors of the urinary system and male genital organs-part a: renal, penile, and testicular tumors. Eur Urol 70:93","journal-title":"Eur Urol"},{"key":"3108_CR8","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471","journal-title":"Ann Surg Oncol"},{"key":"3108_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/JU.0000000000000001","volume":"201","author":"M Assel","year":"2019","unstructured":"Assel M, Sjoberg D, Elders A et al (2019) Guidelines for reporting of statistics for clinical research in urology. J Urol 201:595","journal-title":"J Urol"},{"key":"3108_CR10","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette\u2013Guerin: the CUETO scoring model. J Urol 182:2195","journal-title":"J Urol"},{"key":"3108_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Foerster B, Catto JWF et al (2018) Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73:925","journal-title":"Eur Urol"},{"key":"3108_CR12","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.euf.2016.12.011","volume":"4","author":"A Naselli","year":"2018","unstructured":"Naselli A, Hurle R, Paparella S et al (2018) Role of restaging transurethral resection for T1 Non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:558","journal-title":"Eur Urol Focus"},{"key":"3108_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124","journal-title":"J Urol"},{"key":"3108_CR14","first-page":"4201","volume":"29","author":"L Cormio","year":"2009","unstructured":"Cormio L, Tolve I, Annese P et al (2009) Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer. Anticancer Res 29:4201","journal-title":"Anticancer Res"},{"key":"3108_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.urolonc.2008.08.003","volume":"28","author":"L Cormio","year":"2010","unstructured":"Cormio L, Tolve I, Annese P et al (2010) Retinoblastoma protein expression predicts response to bacillus Calmette\u2013Gu\u00e9rin immunotherapy in patients with T1G3 bladder cancer. Urol Oncol 28:285","journal-title":"Urol Oncol"},{"key":"3108_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3109\/10408363.2014.930412","volume":"51","author":"F Sanguedolce","year":"2014","unstructured":"Sanguedolce F, Bufo P, Carrieri G et al (2014) Predictive markers in bladder cancer: do we have molecular markers ready for clinical use? Crit Rev Clin Lab Sci 51:291","journal-title":"Crit Rev Clin Lab Sci"},{"key":"3108_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.07.001","volume":"117","author":"A Cormio","year":"2017","unstructured":"Cormio A, Sanguedolce F, Musicco C et al (2017) Mitochondrial dysfunctions in bladder cancer: exploring their role as disease markers and potential therapeutic targets. Crit Rev Oncol Hematol 117:67","journal-title":"Crit Rev Oncol Hematol"},{"key":"3108_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jclinpath-2012-200944","volume":"66","author":"PC Chen","year":"2013","unstructured":"Chen PC, Yu HJ, Chang YH et al (2013) Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression. J Clin Pathol 66:113\u2013119","journal-title":"J Clin Pathol"},{"key":"3108_CR19","doi-asserted-by":"publisher","first-page":"25433","DOI":"10.18632\/oncotarget.15989","volume":"8","author":"L Cormio","year":"2017","unstructured":"Cormio L, Sanguedolce F, Cormio A et al (2017) Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget 8:25433","journal-title":"Oncotarget"},{"issue":"23","key":"3108_CR20","first-page":"305","volume":"2018","author":"F Sanguedolce","year":"2016","unstructured":"Sanguedolce F, Brunelli M, D'amuri A et al (2016) Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO classification update with diagnostic algorithm. Biomarkers 2018(23):305","journal-title":"Biomarkers"},{"key":"3108_CR21","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00345-015-1557-9","volume":"33","author":"W Ding","year":"2015","unstructured":"Ding W, Tong S, Gou Y et al (2015) Human epidermal growth factor receptor 2: a significant indicator for predicting progression in non-muscle-invasive bladder cancer especially in high-risk groups. World J Urol 33:1951\u20131957","journal-title":"World J Urol"},{"key":"3108_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00432-018-2593-9","volume":"144","author":"F Sanguedolce","year":"2018","unstructured":"Sanguedolce F, Cormio A, Massenio P et al (2018) Altered expression of HER-2 and the mismatch repair genes MLH1 and MSH2 predicts the outcome of T1 high-grade bladder cancer. J Cancer Res Clin Oncol 144:637","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03108-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-020-03108-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03108-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T10:37:22Z","timestamp":1613299042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-020-03108-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["3108"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03108-z","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}